Trial Profile
A Single Centre, Randomised, Double-blind, Two-way Crossover Trial in Healthy Male Subjects Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 14 May 2014
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemophilia; Thrombasthenia
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 14 May 2014 New trial record